Targeted Genetics Announces Issuance of Additional Adeno-Associated Virus (AAV) Vector Technology Patent
Posted on: Tuesday, 30 August 2005, 09:01 CDT
SEATTLE, Aug. 30 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation today announced the issuance of an additional patent related to the Company's adeno-associated virus (AAV) vector technology. U.S. patent #6,936,466, titled "Transcriptionally Activated AAV Inverted Terminal Repeats (ITRs) for Use with Recombinant AAV Vectors" covers the use of small regulatory control elements in conjunction with sequences within the AAV genome to drive gene expression. The use of vectors described in the patent may help to maximize gene expression efficiency with little or no loss in viral payload.
"We believe that AAV vectors hold great promise in treating a wide variety of diseases," said H. Stewart Parker, President and Chief Executive Officer. "Targeted Genetics is pursuing several approaches, including the approach outlined in this patent, to expand the utility of AAV vectors. Utilizing sequences contained within the AAV genome to drive expression increases our flexibility with respect to vector design, which may allow us to deliver genes that might not ordinarily fit into a single AAV vector. Targeted Genetics continues to broaden its intellectual property portfolio in the area of AAV vector technology, further solidifying its leadership position in this important field of gene delivery."
The combined attributes of persistent expression and a good safety profile make AAV vectors the vector of choice for gene-transfer treatment for a wide variety of chronic disease and the development of viral vaccines. The patent issued today in conjunction with our recently issued patents covering additional methodologies whereby we can increase the carrying capacity of AAV vectors, or produce vectors of a smaller size which lead to metabolically activated recombinant vectors, provides Targeted Genetics with a broad platform of technologies with which to design vectors suitable either to the disease or condition being treated or the genetic sequence being delivered as the therapeutic.
About Targeted Genetics
Targeted Genetics Corporation is a biotechnology company committed to the development and commercialization of innovative targeted molecular therapies for the prevention and treatment of inflammatory arthritis and other acquired and inherited diseases with significant unmet medical need. We use our considerable knowledge and capabilities in the development and manufacturing of gene delivery technologies to advance a diverse product development pipeline. Our product development efforts target inflammatory arthritis, AIDS, congestive heart failure, Huntington's disease, and hyperlipidemia. To learn more about Targeted Genetics, visit our website at http://www.targetedgenetics.com/.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements regarding our intellectual property, research programs and clinical trials, our product development and our potential development platforms including AAV vectors and other statements about our plans, objectives, intentions and expectations. In particular, the statements regarding the Company's pipeline and potential application of this patent to any future product candidates are forward-looking statements. These statements, involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Factors that could affect our actual results include, but are not limited to, results of animal research are not necessarily indicative of results in humans, the timing, nature and results of our research, potential development of alternative technologies or more effective products by competitors, our ability to obtain and maintain regulatory or institutional approvals, our ability to obtain, maintain and protect our intellectual property and our ability to raise capital when needed, as well as other risk factors described in the section entitled "Factors Affecting Our Operating Results, Our Business and Our Stock Price" in our Quarterly Report on Form 10-Q for the period ended June 30, 2005. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectations.
Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation 206-521-7392
Targeted Genetics Corporation
CONTACT: Stacie D. Byars of Targeted Genetics Corporation,+1-206-521-7392
Web site: http://www.targetedgenetics.com/
Source: PRNewswire-FirstCall
Related Articles
- Targeted Genetics Corporation Recommended for Up to $2.4 Million in Funding By Department of Defense
- Targeted Genetics Announces Positive Interim Phase I/II Results for tgAAC94 in Inflammatory Arthritis
- Targeted Genetics Reports Third Quarter 2007 Financial Results
- Targeted Genetics Reports Second Quarter 2007 Financial Results
- Targeted Genetics Completes $19.5 Million Private Equity Financing
- Targeted Genetics Reports First Quarter 2007 Financial Results
- Targeted Genetics Reports Third Quarter 2006 Financial Results
- Targeted Genetics Enters into New Agreement With the International Aids Vaccine Initiative to Support Its Ongoing HIV/AIDS Vaccine Development Program
- Targeted Genetics Reports First Quarter 2006 Financial Results
- Targeted Genetics Announces Todd E. Simpson to Step Down As Chief Financial Officer
 |
 |
User Comments (0)
RSS Feeds